- Home
- BRT vs BNTC Comparison
BRT vs BNTC Comparison
Compare BRT & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRT | BNTC |
|---|---|---|
| Founded | 1972 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 282.3M | 411.4M |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BRT | BNTC |
|---|---|---|
| Price | $13.21 | $10.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $19.75 | ★ $27.67 |
| AVG Volume (30 Days) | 47.5K | ★ 161.7K |
| Earning Date | 03-13-2026 | 05-13-2026 |
| Dividend Yield | ★ 7.35% | N/A |
| EPS Growth | N/A | ★ 80.94 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $97,028,000.00 | N/A |
| Revenue This Year | $2.86 | N/A |
| Revenue Next Year | $6.85 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 1.46 | N/A |
| 52 Week Low | $13.49 | $9.85 |
| 52 Week High | $17.60 | $17.15 |
Technical Indicators
Market Signals| Indicator | BRT | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 29.76 | 36.87 |
| Support Level | N/A | $10.10 |
| Resistance Level | $15.11 | $14.02 |
| Average True Range (ATR) | 0.37 | 0.64 |
| MACD | -0.08 | -0.13 |
| Stochastic Oscillator | 0.35 | 3.32 |
Price Performance
Historical ComparisonAbout BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.